Exelixis saw an 11% share price increase over the last quarter, a period marked by significant achievements including the FDA's approval of CABOMETYX® for treating a broader range of pancreatic and extra-pancreatic neuroendocrine tumors. This regulatory milestone adds to its existing portfolio, potentially enhancing market confidence. During the same period, the company reported robust earnings growth and initiated a $500 million share repurchase program, reflecting a strong financial position. Despite broader market volatility and declines in the tech sector, Exelixis's positive developments helped it outperform general market trends.
Buy, Hold or Sell Exelixis? View our complete analysis and fair value estimate and you decide.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Over the past five years, Exelixis's total shareholder return has reached 118.99%. This impressive performance could be linked to several pivotal developments. For instance, the FDA's March 2025 approval of CABOMETYX® expanded its market for treating certain neuroendocrine tumors, propelling significant revenue potential. Additionally, the company's collaboration efforts, as evidenced by partnerships announced in April 2025 to enhance their clinical trial pipeline, have created avenues for future growth. The expanded indications and clinical trial successes have solidified Exelixis's position in the oncology space, contributing to its broader market appeal and financial success over the extended period.
Enhancements in financial metrics also buoyed shareholder returns. The buyback program initiated in February 2025 for up to US$500 million highlights a focus on shareholder value. Alongside these measures, Exelixis’s financial strength is supported by robust earnings in 2024, where full-year revenue jumped to US$2.17 billion from US$1.83 billion in 2023. This growth trajectory outpaced the broader biotech industry, demonstrating Exelixis's ability to harness its resources and strategic positioning effectively over this period.
Assess Exelixis' future earnings estimates with our detailed growth reports.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:EXEL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Comments